Navigation Links
Vermillion and Johns Hopkins Sign Collaborative Research and License Agreements to Develop Molecular Diagnostic Tests
Date:2/6/2008

Vermillion Obtains Exclusive Rights to Oncology Biomarkers

FREMONT, Calif., Feb. 6 /PRNewswire-FirstCall/ -- Vermillion, Inc. (Nasdaq: VRML), a high-value molecular diagnostics company, today announced the renewal of a long-standing collaboration with Johns Hopkins University on the development of novel biomarkers that can be applied toward disease detection, classification and monitoring of prevalent cancers, including ovarian, breast and prostate. Vermillion will have access to exclusive commercial rights to the discoveries made through the partnership.

"For more than seven years we have had a highly productive relationship with Dr. Daniel W. Chan, Professor of Pathology/Urology/Oncology/ Radiology, Director of the Clinical Chemistry Division in the Department of Pathology and Director for the Center for Biomarker Discovery, and his esteemed team at Johns Hopkins University. Working in tandem with this distinguished institution on the discovery of clinical assays that will ultimately aid in the development of reliable diagnostic tests gives us an opportunity to address serious unmet needs in oncology," said Eric Fung, M.D., Ph.D., Chief Scientific Officer of Vermillion. "This dynamic collaboration has led to the development of our ovarian tumor triage test that has the potential to significantly improve patient outcomes. We look forward to expanding this steadfast relationship."

As part of the collaboration, Vermillion will continue to provide financial support, technical assistance and access to its advanced technology platforms, while Johns Hopkins will continue to contribute cancer serum samples and the clinical and scientific expertise of its physicians and scientists.

About Vermillion

Vermill
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Vermillion (Formerly Ciphergen) Announces $20.5 Million Private Placement of Common Stock
2. Vermillion and Collaborators Discover Protein Biomarker Associated with Peripheral Artery Disease
3. Vermillion, Inc. Announces Receipt Of Notice Of Compliance From Nasdaq
4. Vermillion to Webcast Presentation at the Acumen BioFin 9th Annual Healthcare Conference, November 5-7, New York
5. Johns Hopkins to add Elekta Synergy S(R) to Cancer Treatment Lineup
6. Legendary Earvin Magic Johnson Joins AFL/Signalife Cardiovascular Protection Team
7. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
8. Morria Biopharmaceuticals Plc Appoints Dr. Johnson Lau and Dr. David Sidransky to Board of Directors
9. Entry of Biogenerics and Decreasing Use of Amgens Epogen and Johnson & Johnsons Procrit Will Cause a $2.8 Billion Decline in the Drug Market for Chemotherapy-Induced Anemia by 2016
10. Johnson & Johnson Announces Changes to Accelerate Growth
11. Drugs from Johnson & Johnson/Basilea and Forest Are the Most Promising Antibiotics in the Community-Acquired Pneumonia Pipeline
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/8/2008)...ieve undetectable HCV RNA levels, following 4 week...R) plus Copegus(R) -,...dministered with Pegasys ...wswire-FirstCall/ -- Pharmasset, Inc.,(Nasdaq: VR...th cohort of a,4-week Phase 1 proof-of-concept cli...
(Date:9/8/2008)...ement Consulting announced that it has appointed A... Charlotte, NC (PRWEB) September 8, 2008...ment Consulting] announced that it has appointed A...len joins Symphony from Wellesley Information Serv... developing, and producing national educational co...
(Date:9/6/2008)...elps visitors to electronica 2008 in Munich and co...ctronica information available on the visitor hotl...nning a trip, online registration benefits, a summ...ludes an extensive list of web links to travel, ho... Munich, Germany (PRWEB) September 6, 2008 -...
(Date:9/5/2008)...stitute of Standards and Technology (NIST) and Seo...weak a new class of polymer-based semiconductors t... components of the blend. Their recent resultshow ...gn of practical, large-scale manufacturing techniq...onic displays and other devices.* , Organic semi...
Breaking Biology Technology:Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 2Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 3Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 4Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 5Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 6Symphony Managemnt Consulting Hires New Solutions Director 2Free White Paper Now Available: How to get the most from your visit to electronica 2008 in Munich 2Free White Paper Now Available: How to get the most from your visit to electronica 2008 in Munich 3Bottoms up: Better organic semiconductors for printable electronics 2
...Neurognostics, Inc. , a Wisconsin company speciali...I) products and services, has been honored with a ...tanding Achievements. , ,Last year Neurognostics r...ch (SBIR) Grant from the National Institutes of He...RI-based biomarkers in Parkinson,s disease. Neurog...
... GE Healthcare,s LightSpeed VCT, the world,s firs...gnized today by the Wall Street Journal in the M... Technology Innovation Awards. The annual awards r...s, companies and organizations around the world in...e Wall Street Journal received approximately 750 a...
...rent Energy Systems, Inc. announced today that Dr...Dr. Raman is President of Protium Energy Technolo...gen, fuel cells and alternative energy, based in A..., Inc., is developing Aqueous Phase Reforming (APR...fuel gases and other high value chemicals. APR us...
... Wis.— Renaissance Learning , Inc., a provi...ring tools for pre-K-12 schools and districts, wil...raining and certification office center for all Re...also plans to adjust space needs at other faciliti...s Wisconsin Rapids operation. , ,As part of its Al...
Other Biology Technology:
(Date:9/8/2008)...lif., September 8, 2008For allergy sufferers, the ...without pets or curtains or anything that could tr... extends its Anywhere® product line with the l...abric Spray, a new product to help manage indoor a...rox® Anywhere® Anti-Allergen Fabric Spray ...
(Date:9/8/2008)..., September 2, 2008 -- A new interactive web lesso...raduate students how herbicides are developed. The...te University, has the seal of approval by the Jo...tion and is published in the 2008 issue. , Surp...et today were discovered by random searching. Coll...
(Date:9/7/2008)...s ability to sweat may do more than keep the body ...ise-induced asthma (EIA), a common respiratory con...ing in the September issue of CHEST, the peer-re...ysicians (ACCP), shows that athletes with EIA prod...o not have breathing problems. , Warren Lockett...
(Date:9/7/2008)...A Even closely related plants produce their own n...ed to the individual plant,s specific habitat. Com...e, researchers at the Salk Institute for Biologica...a key enzyme are enough to shift the whole output ...hanges led to a mixture of henbane and tobacco-spe...
Breaking Biology News(10 mins):The Clorox Company's new indoor allergen product reduces common indoor allergens up to 90 percent 2Athletes' 'sweat and tears' linked to asthma 2Athletes' 'sweat and tears' linked to asthma 3How plants fine tune their natural chemical defenses 2How plants fine tune their natural chemical defenses 3Cardiogenesis Reports Fourth Quarter and Full Year 2007 Results 4161 1Cardiogenesis Reports Fourth Quarter and Full Year 2007 Results 4161 2Cardiogenesis Reports Fourth Quarter and Full Year 2007 Results 4161 3Cardiogenesis Reports Fourth Quarter and Full Year 2007 Results 4161 4Cardiogenesis Reports Fourth Quarter and Full Year 2007 Results 4161 5Cardiogenesis Reports Fourth Quarter and Full Year 2007 Results 4161 6Cardiogenesis Reports Fourth Quarter and Full Year 2007 Results 4161 7Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients 1587 1Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients 1587 2Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients 1587 3VaxGen Issues Rebuttal to MedCap Letter 4156 1VaxGen Issues Rebuttal to MedCap Letter 4156 2VaxGen Issues Rebuttal to MedCap Letter 4156 3VaxGen Issues Rebuttal to MedCap Letter 4156 4VaxGen Issues Rebuttal to MedCap Letter 4156 5VaxGen Issues Rebuttal to MedCap Letter 4156 6VaxGen Issues Rebuttal to MedCap Letter 4156 7VaxGen Issues Rebuttal to MedCap Letter 4156 8VaxGen Issues Rebuttal to MedCap Letter 4156 9VaxGen Issues Rebuttal to MedCap Letter 4156 10VaxGen Issues Rebuttal to MedCap Letter 4156 11Tempo Participacoes S A Announces Increase of 16 8 25 in Net Revenue and of 46 3 25 in EBITDA for 2007 15024 1
... the species known as social amoebas has been plot...provide important clues to the evolution of life o...logist Professor Sandie Baldauf, of the University... of the University of Dundee, have produced the fi...species of social amoeba. , Using this family t...
... haphazardly flail about looking for a host but se...d identify potential hosts by their emissions, acc.... , "We are interested in how plants respond to th...nteractions," says Dr. Consuelo M. De Moraes, assi... to see how little was available on how above-grou...
...lebee will carry its pollen next, you have to lite...raging style that,s been successful, they are more...n learning something new," says Rebecca Flanagan, ...Milwaukee (UWM). , Flanigan and her professor, J...as they gather pollen ?which plant species the bee...
...ntified a key enzyme responsible for triggering a ... according to new study findings published online ...archers from Virginia Commonwealth University, the...dical College in New York sets the stage for devel... control allergic disease ?the sixth leading cause...
Other Biology News:Scientists' cell discovery unearths evolutionary clues 2Scientists' cell discovery unearths evolutionary clues 3Parasitic plants sniff out hosts 2Parasitic plants sniff out hosts 3Researchers find that bumblebees' flower choice matters 2Researchers find that bumblebees' flower choice matters 3Researchers find that bumblebees' flower choice matters 4Key molecular signaling switch involved in allergic disease identified 2
...it Polyclonal to Human CELSR3 CELSR3 is an Orpha...ene is expressed during development at sites of ac...ain, spinal cord, dorsal root ganglion, and eye. E...is, blood, brain, colon, heart/melanocyte/uterus, ...
...ination inline heater plus multi-channel focal dru...ug wash-out with a high-flow bath line while quick...e Perfusion Pencil.® Steady 37°C at 5 ml/...ip. Advanced auto-tuning temperature lock Desig...
Immunogen: purified recombinant human angiogenin expressed in E. coli . Physical form: Lyophilized from a 0.2 μm filtered solution in phosphate buffered saline. Titertest method: ELISA (c).
CKB Antibody (N-term) Antigen: This antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide selected within aa 1~100 of human CKB. Molecular Weight: 42644 Da
Biology Products: